This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: Q85.8 / Special Copayment Reduction: V216 / Re-approval cycle: 5 years |
| B. Synonyms | Peutz-Jeghers syndrome, Sturge-Weber(-Dimitri) syndrome |
| C. Included diseases | VHL syndrome, Peutz-Jeghers syndrome, Sturge-Weber syndrome — pathogenesis, genetics, and clinical picture of the three diseases described separately |
| 1. History | Historical description and gene identification of each disease: VHL/PJS/SWS |
| 2. Epidemiology | VHL: 1/36,000; PJS: 1/50,000~200,000; SWS: 1/20,000~50,000 |
| 3. Etiology and genetics | VHL: 3p25 VHL gene; PJS: 19p13 STK11; SWS: GNAQ somatic mutation |
| 4. Pathophysiology | VHL: HIF-α stabilization; PJS: dysregulation of AMPK-mTOR; SWS: formation of vascular malformations |
| 5. Clinical features | VHL: hemangioblastoma, renal cell carcinoma; PJS: gastrointestinal polyps, pigmented macules; SWS: port-wine stain, epilepsy |
| 6. Diagnostic criteria | Clinical and molecular diagnostic criteria for each disease: VHL/PJS/SWS |
| 7. Differential diagnosis | Sporadic renal cell carcinoma, familial polyposis, isolated port-wine stain, etc. |
| 8. Laboratory and imaging findings | MRI, abdominal imaging, gastrointestinal endoscopy, EEG, ophthalmic examination |
| 9. Treatment | VHL: belzutifan, surgery; PJS: endoscopic polypectomy; SWS: anticonvulsants, laser |
| 10. Complications | VHL: metastatic renal cell carcinoma; PJS: gastrointestinal cancer; SWS: glaucoma, cognitive decline |
| 11. Prognosis | VHL: early detection of renal cell carcinoma determines prognosis; PJS: increased cancer risk; SWS: seizure control is key |
| 12. Prevention | VHL/PJS: genetic counseling, PGT-M; multi-organ surveillance protocols |
| 13. References | Jonasch E et al. (2021) Belzutifan for VHL disease and 9 more papers |
In 1895, the German ophthalmologist Eugen von Hippel first described retinal hemangioblastoma. Later, in 1927, the Swedish pathologist Arvid Lindau systematically described a syndrome in which cerebellar hemangioblastoma and cystic renal lesions occur together, and the name 'von Hippel-Lindau disease,' combining the names of the two, was established. In 1993, Latif et al. identified the VHL tumor suppressor gene on chromosome 3p25, and it was later shown that the VHL protein is the substrate-recognition subunit of an E3 ubiquitin ligase that mediates degradation of hypoxia-inducible factor (HIF-α). This discovery contributed greatly to research on renal cell carcinoma and angiogenesis, and led to the development of belzutifan, a HIF-2α inhibitor.
In 1921, the Dutch physician Jan Peutz first reported cases in which gastrointestinal polyps and pigmented macules of the lips and mucosa occurred in a familial pattern. In 1949, the American physician Harold Jeghers and colleagues systematized the disease through 10 additional cases, and the name Peutz-Jeghers syndrome was established. In 1998, Hemminki et al. confirmed that mutations in the STK11 (LKB1) gene on chromosome 19p13.3 cause PJS. STK11 is a tumor suppressor gene that, as the upstream kinase of AMPK, is involved in cellular energy sensing and regulation of the mTOR pathway.
In 1879, the British neurologist William Allen Sturge first described a patient with a facial port-wine stain, glaucoma, and epilepsy. In 1922, the neurologist Frederick Parkes Weber additionally described radiographic findings characterized by intracranial calcification, expanding the clinical spectrum of this syndrome. The name of the Russian neurologist Dimitri is also included in some names. In 2013, Shirley et al. discovered that the R183Q somatic mutation of the GNAQ gene causes SWS, establishing that SWS is due not to germline inheritance but to a somatic mutation early in development.
The birth incidence of VHL syndrome is estimated at about 1/36,000. The number of patients worldwide is estimated at about 200,000. It is inherited in an autosomal dominant manner, and the proportion of de novo mutations is about 20%. The phenotype varies according to VHL genotype type (type 1, 2A, 2B, 2C).
The birth incidence of Peutz-Jeghers syndrome is 1/50,000–200,000, varying by reporting institution. There is no sex difference. The proportion of de novo mutations is about 25–50%, and about 20–30% of PJS patients have no identified STK11 mutation.
The incidence of Sturge-Weber syndrome is estimated at about 1/20,000–50,000, but because it is caused by a GNAQ somatic mutation and is not heritable, most cases have no family history. SWS accompanies about 10–15% of infants with a facial port-wine stain.
The VHL gene is located on chromosome 3p25.3 and has 3 exons encoding a 213-amino-acid protein (pVHL). The key function of pVHL is to promote oxygen-dependent degradation of HIF-α (hypoxia-inducible factor-α). Under normoxic conditions, when proline residues of HIF-α are hydroxylated by prolyl hydroxylases (PHD), pVHL recognizes them and ubiquitinates HIF-α through the E3 ubiquitin ligase complex (elongin B/C, Cullin-2, RBX1) for proteasomal degradation. With VHL mutation, pVHL cannot bind HIF-α, so HIF-α is stabilized regardless of oxygen concentration, and genes related to angiogenesis and cell proliferation such as VEGF, PDGF, EPO, and GLUT-1 are upregulated. There are genotype–phenotype correlations according to VHL genotype: mutation type 1 (deletion/truncation) has renal cell carcinoma but no pheochromocytoma; type 2 (missense) is accompanied by pheochromocytoma; type 2B has renal cell carcinoma + pheochromocytoma + hemangioblastoma.
The causative gene is STK11 (LKB1), located on chromosome 19p13.3, with 9 exons encoding a 433-amino-acid serine-threonine kinase. STK11 is the upstream kinase that phosphorylates and activates AMPK (AMP-activated protein kinase), and AMPK is a key regulator that inhibits mTORC1 under energy-deficient conditions. With loss of STK11, AMPK is not activated, mTORC1 is upregulated, and cell proliferation and tumor formation are promoted. STK11 also performs various tumor-suppressor functions, such as maintaining cell polarity, promoting p53-dependent apoptosis, and phosphorylating myosin light chain. The mode of inheritance is autosomal dominant.
SWS is caused by a somatic mutation (R183Q, c.548G>A) in the GNAQ (guanine nucleotide-binding protein G(q) subunit alpha) gene. GNAQ encodes the Gq α subunit, and the R183Q mutation abolishes intrinsic GTPase activity, keeping Gq in a constitutively active form. This simultaneously activates the PLCβ-IP3-Ca²⁺, RAS-MAPK, and PI3K-AKT pathways, inducing vascular endothelial hyperproliferation and formation of malformed vessels. The mutation arises early in development (in an embryo of few cells) and appears in a mosaic form, so occurrence is sporadic rather than familial. The same GNAQ R183Q variant is also identified in other vascular malformations involving port-wine stains (some cases of Klippel-Trénaunay syndrome).
The key consequence of loss of VHL tumor-suppressor function is stabilization of HIF-2α (mainly) and HIF-1α. As transcription factors, these form dimers with HIF-1β (ARNT) in the nucleus and promote transcription of VEGFA, VEGFB, PDGFB, EPO, GLUT1, LDHA, carbonic anhydrase IX (CA-IX), and others through hypoxia response elements (HRE). Persistent VEGF secretion promotes tumor angiogenesis, and increased EPO causes paraneoplastic polycythemia. Renal cell carcinoma (clear cell type) is a main target of targeted therapies such as sunitinib and pazopanib, which target the VEGFR/PDGFR activation induced by VHL loss of function. Belzutifan, a selective HIF-2α inhibitor, directly targets HIF-2α in VHL disease–associated tumors.
With loss of STK11, AMPK is not activated, and mTORC1 is constitutively activated. mTORC1 promotes ribosome synthesis and translation through phosphorylation of S6K1 and increases cap-dependent mRNA translation through phosphorylation of 4E-BP1. Loss of STK11 also leads to abnormalities of cell-polarity proteins (PAR complex), disrupting intestinal epithelial tissue architecture, which contributes to the distinctive histology of hamartomatous polyps (arborizing villi with a smooth muscle core). Because PJS polyps are hamartomas, they are not considered direct precancerous lesions, but separate dysplastic changes or adenocarcinomas arising from gastrointestinal epithelial cells occur at a markedly higher frequency in PJS patients.
Constitutive Gq signaling activation by the GNAQ R183Q mutation promotes proliferation and survival of vascular endothelial cells through PLCβ activation → IP3/DAG production → Ca²⁺ release and PKC activation and RAS-MEK-ERK activation. Leptomeningeal angiomatosis forms through abnormal persistence and hyperproliferation of leptomeningeal vessels during embryonic development, and causes chronic ischemia, oxidative stress, and neuronal loss in the adjacent cortex. This is the pathophysiological basis of epilepsy, cortical atrophy, and calcification. The port-wine stain is formed by dilation and proliferation of dermal capillaries and venules. Glaucoma arises from abnormal aqueous outflow when the port-wine stain is distributed on the eyelid or conjunctiva.
Major organ lesions include central nervous system hemangioblastoma (cerebellum, brainstem, spinal cord), retinal hemangioblastoma, clear cell renal cell carcinoma (clear cell RCC), multiple renal cysts, pancreatic cysts and pancreatic neuroendocrine tumors (pNET), pheochromocytoma, paraganglioma, and endolymphatic sac tumor (ELST). Cerebellar hemangioblastoma occurs in 70–80% of VHL patients and, as a cystic tumor, causes increased intracranial pressure, cerebellar ataxia, and headache. Retinal hemangioblastoma occurs in 50–60% and is the main cause of vision loss. ELST causes hearing loss, tinnitus, and vertigo. Paraneoplastic polycythemia occurs in about 20% of VHL patients.
The most characteristic finding of PJS is the coexistence of mucocutaneous pigmented macules and hamartomatous GI polyps. The pigmented macules appear as blue-gray or brown macules 1–5 mm in size on the lips, oral mucosa, nose, and fingertips, and tend to fade with age. Gastrointestinal polyps are most common in the small intestine (especially the jejunum and ileum) and also occur in the colon, stomach, and duodenum. Intussusception caused by small intestinal polyps causes abdominal pain, bowel obstruction, and bleeding. PJS patients have a markedly increased lifetime risk of gastrointestinal cancer (small intestine, colon, stomach), breast cancer, cervical adenocarcinoma, well-differentiated ovarian Sertoli cell tumor, and lung cancer.
The three main clinical findings of SWS are ① facial port-wine stain (PWS), ② leptomeningeal angiomatosis, and ③ glaucoma. When the port-wine stain follows the distribution of the first branch of the trigeminal nerve (upper orbital region), the likelihood of brain involvement is high. Epilepsy occurs in about 75–90% of SWS patients and usually presents as focal seizures within the first 1–2 years of life. As unilateral cortical atrophy progresses, hemiparesis, cognitive decline, and learning disabilities follow. Glaucoma may initially progress through abnormal aqueous outflow without elevated intraocular pressure, so early measurement of intraocular pressure is important.
Clinical diagnosis: ① in a patient with a family history (+), one of: 1 hemangioblastoma, renal cell carcinoma, or pheochromocytoma; ② in a patient without a family history (-), 2 or more central nervous system hemangioblastomas, or a hemangioblastoma + one of renal cell carcinoma/pheochromocytoma/pancreatic lesion. Molecular diagnosis: identification of a pathogenic germline variant in the 3p25 VHL gene.
Clinical diagnosis (one of the following): ① 3 or more histologically confirmed PJS polyps; ② 1 or more PJS polyps in a patient with a family history (+); ③ characteristic mucocutaneous pigmented macules in a patient with a family history (+); ④ mucocutaneous pigmented macules + 1 or more PJS polyps without a family history. Molecular diagnosis: identification of a pathogenic variant in 19p13 STK11.
Clinical diagnosis: facial port-wine stain in the distribution of the first branch of the trigeminal nerve + ipsilateral leptomeningeal angiomatosis (contrast enhancement on MRI) + glaucoma or ocular vascular abnormalities. Cases with only an isolated PWS or with only PWS + glaucoma may be classified as an incomplete form. Identification of the GNAQ somatic mutation supplements the diagnosis, but because of somatic mosaicism it may not be detected in peripheral blood testing, so biopsy of lesional tissue is necessary.
VHL vs sporadic renal cell carcinoma: in clear cell renal cell carcinoma under age 40 or multiple/bilateral renal lesions, VHL is suspected first and germline testing is performed.
PJS vs juvenile polyposis: juvenile polyposis (SMAD4/BMPR1A mutations) consists of hamartomas without adenomatous change and has no pigmented macules. Histologically, PJS polyps are characterized by an arborizing structure with a smooth muscle core.
PJS vs PTEN hamartoma syndrome (Cowden syndrome): hamartomas and lipomas due to PTEN mutation, with increased risk of thyroid and breast cancer. Oral mucosal papillomas are numerous.
SWS vs isolated port-wine stain: a PWS distributed only over the 2nd and 3rd branches of the trigeminal nerve has a low likelihood of brain involvement. Brain MRI is recommended only when there is frontal/eyelid distribution (1st branch of the trigeminal nerve).
SWS vs Klippel-Trénaunay syndrome: limb vascular malformations with soft tissue and bone hypertrophy. The same GNAQ variant is identified in some.
VHL: brain/spinal MRI (gadolinium contrast) to evaluate hemangioblastoma; abdominal MRI (renal cysts, renal cell carcinoma, pNET); 24-hour urine catecholamines and metanephrines (pheochromocytoma); fundus examination (fluorescein angiography); hearing test and temporal bone MRI (ELST); hemoglobin and hematocrit (paraneoplastic polycythemia). Serum VEGF is used as an adjunct for tracking tumor burden.
PJS: esophagogastroduodenoscopy (EGD) + colonoscopy + small bowel capsule endoscopy or small bowel MRI (MR enterography); recording of small intestinal polyp size and number; breast MRI (women); pelvic ultrasound/MRI (women: uterus and ovaries); testicular ultrasound (men: Sertoli cell tumor).
SWS: brain MRI (T1 contrast enhancement to confirm leptomeningeal angiomatosis; T2 FLAIR for cortical atrophy and gliosis; SWI/T2* for calcification); electroencephalography (EEG: classification of seizure type); intraocular pressure measurement and visual field testing (glaucoma); dermatologic evaluation (extent and branch distribution of PWS).
Belzutifan (Welireg®), a selective HIF-2α inhibitor, received FDA approval in 2021 and is used to treat renal cell carcinoma, pancreatic pNET, and retinal/CNS hemangioblastoma in VHL disease. In the LITESPARK-004 trial, response rates reached 49% for renal cell carcinoma, 30% for CNS hemangioblastoma, and 83% for pNET. For cerebellar and spinal hemangioblastomas, surgery (microneurosurgical resection) is the standard treatment when symptomatic or increasing in size. Retinal hemangioblastomas are treated with laser photocoagulation, cryotherapy, or photodynamic therapy. Renal cell carcinoma is observed when 3 cm or smaller, and partial nephrectomy (nephron-sparing surgery) is performed when it grows to 3 cm or more. Pheochromocytoma is treated with laparoscopic adrenalectomy after α-blocker pretreatment, in consultation between endocrinology and surgery.
When intussusception due to small intestinal polyps occurs, emergency surgery or hydrostatic reduction is performed. Large polyps of the small and large intestine (diameter >1.5 cm) are removed endoscopically or surgically to prevent intussusception and bleeding. Small intestinal polyps are monitored with capsule endoscopy or double-balloon endoscopy, and endoscopic polypectomy is performed where possible. In accordance with cancer surveillance protocols, colonoscopy (every 2–3 years), upper endoscopy (every 2–3 years), small bowel MRI (every 2–3 years), breast MRI, and abdominal ultrasound are performed regularly. A reduction of PJS polyps with mTOR inhibitors has been reported in small studies, but this has not yet been established as standard treatment.
For epilepsy, anticonvulsants (carbamazepine, oxcarbazepine, levetiracetam, etc.) are used, and for drug-resistant epilepsy, the ketogenic diet, vagus nerve stimulation, and epilepsy surgery (resection of the affected cortex) are considered. Low-dose aspirin (3–5 mg/kg/day) may be used to prevent migraine-like headache episodes and thrombosis. Glaucoma treatment is individualized, using intraocular pressure–lowering eye drops (prostaglandin analogs, beta-blockers) or surgical treatment (trabeculotomy, trabeculectomy). For port-wine stains, the pulsed dye laser (PDL, 585/595 nm) is the standard treatment, and early (infancy) initiation is effective. Clinical trials of a MEK inhibitor (trametinib) for SWS are ongoing.
VHL: metastatic clear cell renal cell carcinoma is the main cause of death, and if renal cell carcinoma is left untreated beyond 3 cm, the risk of metastasis rises sharply. Hydrocephalus and brainstem compression due to cerebellar hemangioblastoma can cause acute neurological deterioration. Spinal hemangioblastoma causes paralysis and bladder dysfunction depending on its location. Irreversible hearing loss due to ELST is also an important complication.
PJS: gastrointestinal cancer (small intestinal, colon, gastric cancer) has been reported to reach a lifetime risk of 57–93% in PJS patients, so regular surveillance is essential. Emergency surgery and bowel resection for small intestinal intussusception carry a risk of short bowel syndrome. Female PJS patients have an increased risk of breast cancer (54%), malignant cervical adenocarcinoma (10%), and ovarian cancer.
SWS: repeated seizures due to drug-resistant epilepsy lead to progressive unilateral cortical atrophy, which causes hemiparesis, cognitive decline, and hemianopia. Untreated glaucoma results in irreversible optic nerve damage and blindness. Stroke-like episodes may occur, with rapid neurological deterioration.
VHL syndrome: in the past the median age at death was 40–50 years, but prognosis is improving markedly with the introduction of regular surveillance programs and the use of targeted therapies such as belzutifan. Early detection of renal cell carcinoma and kidney-sparing surgery are key to prognosis. Because the risks of renal cell carcinoma and pheochromocytoma differ by VHL variant type (type 1 vs 2B), genotype-tailored surveillance is needed.
PJS: where cancer surveillance programs are established, cancer-related mortality decreases. Repeated surgery for small intestinal intussusception increases the risk of short bowel syndrome, and early endoscopic polypectomy is emphasized to minimize this. Overall life expectancy may be shortened by 10–15 years compared with the general population.
SWS: the timing of seizure onset and whether seizures are controlled are the most important determinants of neurodevelopmental prognosis. When seizures begin early and progress to drug resistance, cognitive impairment and behavioral problems are severe. Early epilepsy surgery (hemispherectomy, cortical resection) is effective in selected patients for achieving seizure freedom and improving neurodevelopment.
Because VHL and PJS are autosomal dominant genetic disorders, genetic counseling and preimplantation genetic testing (PGT-M) are possible. When affected patients plan a pregnancy, selection of carrier embryos is possible through consultation with a reproductive genetics specialist and PGT-M or prenatal genetic testing. Through predictive genetic testing (cascade testing) of family members (first-degree relatives), asymptomatic carriers are identified early and enrolled in surveillance programs.
By adhering to multi-organ surveillance protocols, VHL-related renal cell carcinoma and PJS-related gastrointestinal cancer can be detected and treated early. VHL patients undergo annual fundus examination and MRI/ultrasound every 1–2 years according to international guidelines such as those of the VHL Alliance. PJS patients begin regular surveillance from childhood, including small bowel MRI (every 3 years) and colonoscopy and upper endoscopy (every 2–3 years).
Because SWS results from a somatic mutation, genetic prevention does not apply. However, prompt initiation of epilepsy treatment through early diagnosis and early detection and treatment of glaucoma are key to preventing complications. Newborns with a facial port-wine stain should undergo immediate ophthalmologic and neurologic evaluation, and brain MRI is recommended when the stain is in the distribution of the first branch of the trigeminal nerve.